How should acute coronary syndrome presenting as a non‑ST‑segment elevation myocardial infarction be managed in a patient who is 10 weeks pregnant (first trimester)?

Management of NSTEMI at 10 Weeks Gestation

For a pregnant patient at 10 weeks with NSTEMI, proceed with invasive coronary angiography and percutaneous coronary intervention (PCI) using bare metal stents via radial access, combined with aspirin and clopidogrel, while avoiding ACE inhibitors, ARBs, prasugrel, and ticagrelor.

Immediate Invasive Strategy

An invasive approach is indicated for NSTEMI in pregnancy, as this represents non-ST elevation ACS with high-risk criteria 1. The ESC guidelines specifically recommend invasive management for non-ST elevation ACS with risk criteria, including NSTEMI 1. This takes precedence over conservative management, which should only be considered for non-ST elevation ACS without risk criteria 1.

Procedural Considerations

• Use radial artery access over femoral to reduce bleeding and vascular complications 2
• Minimize radiation exposure to the fetus through:
  • Lead shielding of the abdomen and pelvis
  • Reduced fluoroscopy time
  • Optimized angulation to keep the beam away from the uterus 3
• Use bare metal stents only - drug-eluting stents should be avoided as their safety in pregnancy is unknown and they require prolonged dual antiplatelet therapy 1
• Consider intracoronary imaging to guide PCI in complex lesions 2

Critical First Trimester Consideration

At 10 weeks gestation, you are in the period of organogenesis where radiation exposure carries the highest teratogenic risk 1. However, the maternal mortality risk from untreated NSTEMI outweighs fetal radiation risk. The key is aggressive radiation protection measures while not compromising the quality of the intervention 3.

Antiplatelet Therapy

Initiate dual antiplatelet therapy with:

• Aspirin (low-dose) - considered relatively safe in pregnancy 1
• Clopidogrel - use only when strictly needed (as after stenting) and for the shortest duration possible 1

Avoid:

• Ticagrelor and prasugrel - safety unknown in pregnancy; thienopyridines should be minimized 1
• The standard 12-month dual antiplatelet therapy duration may need modification based on bleeding risk and delivery timing

Medical Therapy Contraindications

Absolutely contraindicated:

• ACE inhibitors 1
• Angiotensin receptor blockers (ARBs) 1
• Renin inhibitors 1

Relatively safe:

• Beta-blockers 1
• Low-dose aspirin 1

Thrombolysis Alternative

Thrombolytic therapy should be reserved only for life-threatening ACS when PCI is completely inaccessible 1. Although recombinant tissue plasminogen activator does not cross the placenta, it can induce subplacental bleeding complications 1. Given that PCI is preferred and you have access to it, proceed directly to catheterization.

Etiology Considerations

Be aware that spontaneous coronary artery dissection is one of the most common causes of ACS in pregnant patients 4. The angiogram will help differentiate this from atherosclerotic disease, which has important management implications. If coronary dissection is identified, conservative management may be preferred over stenting in some cases, though this depends on hemodynamic stability 1.

Common Pitfalls to Avoid

1. Delaying invasive strategy due to pregnancy - maternal survival is paramount, and untreated NSTEMI carries unacceptable mortality risk
2. Using drug-eluting stents - stick with bare metal stents despite higher restenosis rates 1
3. Prescribing ACE inhibitors/ARBs for post-MI remodeling - these are teratogenic 1
4. Excessive radiation concern leading to inadequate imaging - use protection measures but complete the procedure properly 3

Multidisciplinary Coordination

Involve cardiology, maternal-fetal medicine, and interventional cardiology immediately. Document shared decision-making regarding radiation exposure and medication risks 3. Plan for high-risk obstetric follow-up at a tertiary center 5.